Japan · Delayed Price · Currency is JPY PhoenixBio Statistics
Total Valuation
PhoenixBio has a market cap or net worth of JPY 1.59 billion. The enterprise value is 928.45 million.
| Market Cap | 1.59B |
| Enterprise Value | 928.45M |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PhoenixBio has 4.07 million shares outstanding. The number of shares has increased by 0.50% in one year.
| Current Share Class | 4.07M |
| Shares Outstanding | 4.07M |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 18.99% |
| Owned by Institutions (%) | 6.35% |
| Float | 1.68M |
Valuation Ratios
The trailing PE ratio is 12.71.
| PE Ratio | 12.71 |
| Forward PE | n/a |
| PS Ratio | 1.02 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | 28.42 |
| P/OCF Ratio | 23.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.00, with an EV/FCF ratio of 16.58.
| EV / Earnings | 7.43 |
| EV / Sales | 0.59 |
| EV / EBITDA | 8.00 |
| EV / EBIT | 11.19 |
| EV / FCF | 16.58 |
Financial Position
The company has a current ratio of 4.40, with a Debt / Equity ratio of 0.31.
| Current Ratio | 4.40 |
| Quick Ratio | 3.44 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 4.18 |
| Debt / FCF | 8.66 |
| Interest Coverage | 20.75 |
Financial Efficiency
Return on equity (ROE) is 8.57% and return on invested capital (ROIC) is 9.37%.
| Return on Equity (ROE) | 8.57% |
| Return on Assets (ROA) | 2.32% |
| Return on Invested Capital (ROIC) | 9.37% |
| Return on Capital Employed (ROCE) | 4.56% |
| Weighted Average Cost of Capital (WACC) | 4.88% |
| Revenue Per Employee | 22.68M |
| Profits Per Employee | 1.81M |
| Employee Count | 69 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.14 |
Taxes
In the past 12 months, PhoenixBio has paid 6.00 million in taxes.
| Income Tax | 6.00M |
| Effective Tax Rate | 4.58% |
Stock Price Statistics
The stock price has increased by +0.26% in the last 52 weeks. The beta is 0.34, so PhoenixBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +0.26% |
| 50-Day Moving Average | 442.84 |
| 200-Day Moving Average | 463.10 |
| Relative Strength Index (RSI) | 29.64 |
| Average Volume (20 Days) | 9,825 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PhoenixBio had revenue of JPY 1.57 billion and earned 125.00 million in profits. Earnings per share was 30.75.
| Revenue | 1.57B |
| Gross Profit | 1.20B |
| Operating Income | 83.00M |
| Pretax Income | 131.00M |
| Net Income | 125.00M |
| EBITDA | 116.00M |
| EBIT | 83.00M |
| Earnings Per Share (EPS) | 30.75 |
Balance Sheet
The company has 1.15 billion in cash and 485.00 million in debt, with a net cash position of 663.00 million or 162.89 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 485.00M |
| Net Cash | 663.00M |
| Net Cash Per Share | 162.89 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 381.32 |
| Working Capital | 1.27B |
Cash Flow
In the last 12 months, operating cash flow was 68.00 million and capital expenditures -12.00 million, giving a free cash flow of 56.00 million.
| Operating Cash Flow | 68.00M |
| Capital Expenditures | -12.00M |
| Depreciation & Amortization | 33.00M |
| Net Borrowing | -69.00M |
| Free Cash Flow | 56.00M |
| FCF Per Share | 13.76 |
Margins
Gross margin is 76.68%, with operating and profit margins of 5.30% and 7.99%.
| Gross Margin | 76.68% |
| Operating Margin | 5.30% |
| Pretax Margin | 8.37% |
| Profit Margin | 7.99% |
| EBITDA Margin | 7.41% |
| EBIT Margin | 5.30% |
| FCF Margin | 3.58% |
Dividends & Yields
PhoenixBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.50% |
| Shareholder Yield | -0.50% |
| Earnings Yield | 7.85% |
| FCF Yield | 3.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PhoenixBio has an Altman Z-Score of 1.97 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 7 |